* BMI between 30 - 49.9 kg/m2 and/or diagnosed with type 2 diabetes.
* Currently prescribed and using GLP-1 receptor therapy for at least 4 weeks.
* Own a smartphone (Android or iOS) with an active data plan to support app-based intervention delivery.
* Residing anywhere in the United States.
* Must be willing and able to reduce caloric intake.
* Be free of major health or psychiatric diseases, drug, or alcohol dependency.
* Willing to sign informed consent.
You may not be if
• Presence of type 1 diabetes mellitus
* Severe complications, including but not limited to proliferative retinopathy, severe peripheral neuropathy, nephropathy requiring dialysis, active foot ulcers, or recent hospitalization for diabetic ketoacidosis or hyperosmolar hyperglycemic state within the past 6 months.
* Current or recent (within 6 months) participation in another structured weight loss program or clinical trial that may interfere with study outcomes.
* Pregnancy, breastfeeding, or plans to become pregnant during the study period.
* Current use of another investigational weight loss device or medication.
* Diagnosed eating disorders (e.g., anorexia nervosa, bulimia nervosa, binge eating disorder) or other psychiatric conditions that may affect adherence to behavioral interventions, as determined by study staff.
* Severe cardiovascular, hepatic, renal, or pulmonary disease that would limit participation in moderate physical activity or dietary modification.
* Active cancer treatment (chemotherapy, radiation, or surgery) within the past 12 months.
* Substance use disorder or alcohol dependency within the past 12 months.
* Cognitive impairment or any medical or mental condition that would interfere with the ability to understand or comply with study procedures.
* Lack of reliable internet or smartphone access, or unwillingness to use a mobile app for tracking and communication.
